standard care
[용어속성] Term
Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: A retrospective study from Burkina Faso and simulated case analysis
사하라 사막 이남 아프리카의 COVID-19 사례 중 임상 관리 및 사망률: 부르키나 파소의 후향적 연구 및 모의 사례 분석
Article
[키워드] 95% CI
adjusted
African
age
aggregate
Americas
Analysis
analyzed
Asia
Burkina Faso
Care
Caregivers
case fatality rates
clinical
Clinical characteristics
clinical information
Clinical management of SARS-CoV-2 infection: convalescent plasma
Community
Comorbidities
component
conducted
convalescent plasma
country
COVID-19
COVID-19 case
COVID-19 cases
COVID-19 mortality
Critical
curative
death
Deceased
Delayed
demographic
demographic and clinical characteristics
demographic data
diabete
diabetes
disparity
distribution
distributions
effect sizes
Effectiveness
epidemiological
Europe
evaluate
fatality
Health systems strengthening
healthcare providers
Highlights
Hospitalized
hypertension
Impact
information
Intervention
Investment
Logistic regression analysis
maintenance
majority
male
management
Mortality
over
oxygen
Oxygen therapy
Patient
patients receiving oxygen
Population
prevalent
receiving
reduce
reduced
regression analysis
reported
respiratory
respiratory illnesses
Result
Retrospective study
risk
risk factor
SARS-COV-2 infection
seeking
Sex
significantly higher
significantly lower
SSA
standard care
sub-Saharan Africa
suggested
survival
the epidemic
therapeutic
therapy
treating COVID-19
Treatment
underlying condition
underlying conditions
West
[DOI] 10.1016/j.ijid.2020.09.1432 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ijid.2020.09.1432 PMC 바로가기 [Article Type] Article
Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
Review
[키워드] 95% confidence interval
Adverse
Affect
Antiviral
Antiviral treatment
antiviral treatments
article
body temperature
Clinical outcome
Combination
Consensus
cough relief
COVID-19
COVID-19 disease
COVID-19 patient
Effect
Efficacy
Efficacy and safety
eight
evaluated
event
Evidence
favorable effect
HIV
Hospital stay
Hospitalization
Human immunodeficiency virus
invasive mechanical
Invasive mechanical ventilation
item
Kaletra
largest trial
less
Lopinavir/ritonavir
Meta-analysis
Mortality
MOST
not significant
Patient
positive
protocol
radiological progression
reached
recovery
reduce mortality
reported
Reporting
Research
review
risk
Safety
selected
shown
standard care
systematic review
Therapies
Treatment
umifenovir
virological cure
[DOI] 10.3390/tropicalmed5040180 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/tropicalmed5040180 PMC 바로가기 [Article Type] Review
Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project)
코로나19 예방 백신: 개별 환자 데이터를 포함하는 네트워크 메타 분석을 통한 살아있는 체계적인 검토를 위한 프로토콜(The LIVING VACCINE Project)
Protocol
[키워드] active placebo
acute respiratory syndrome
acute respiratory syndrome coronavirus
aggregate data meta-analyses
all age groups
all-cause mortality
analyzed
approach
assessment
assessments
best
cause
CENTRAL
certainty
certainty of evidence
Clinical research
clinical trial registries
clinical trial registry
clinical trials
confidence
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
database
dendritic
dendritic cell
described
development
Diagnosis
disease
Effect
events
Evidence
GRADE
identify
inactivated
include
individual patient data meta-analyses
life
Messenger RNA
meta-analyses
Mortality
network
Network meta-analysis
non-serious adverse
non-serious adverse events
not limited
observational studies
observational study
once a week
outcome
pandemic
participant
patient data
Placebo
prevalent
Prevent
Primary outcomes
Protein
Protein subunit
protocol
Quality of life
randomized clinical trial
randomized clinical trials
Research
respiratory
risk of bia
SARS-CoV-2
secondary
Secondary outcomes
Serious Adverse Events
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
Spread
standard care
supplementary material
systematic review
Trial
trial sequential analyses
Vaccine
vaccine for COVID-19
Vaccines
Viral
Viral vector
[DOI] 10.1186/s13643-020-01516-1 PMC 바로가기 [Article Type] Protocol
[DOI] 10.1186/s13643-020-01516-1 PMC 바로가기 [Article Type] Protocol
CovEMERALD: Assessing the feasibility and preliminary effectiveness of remotely delivered Eye Movement Desensitisation and Reprocessing following Covid-19 related critical illness: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
24 hours
activity monitor
addition
adverse event
age
ALEA
anticipated
Anxiety
Appetite
Assessing
assigned
blinded
Care
case report form
clinical
Cognitive impairment
Cohort
control arm
Council
COVID-19
Critical
Data analysis
Depression
description
determine
Diagnosis
discharge
discharge home
dissemination
Effectiveness
eight
element
eligible patient
Emdr
episode
excluded
expected
exploratory
expressed
eye
Eye-movement desensitisation and reprocessing
feasibility
Final
Follow-up
group
Group allocation
hospital
hospital discharge
IMPROVE
incidence
intensive care
intensive care unit
Intervention
intervention arm
intervention group
measure
mechanical ventilation
Mortality
movement
number
nutrition
objective
outcome
participant
Patient
patient reported outcome
physical
physical activity
polymerase chain
positive
Primary outcome
protocol
Psychological
Psychology
PTSD
Quality of life
randomised
randomised controlled
randomised controlled trial
Randomly
receive
recent
recruited
recruitment
Registered
reported
Sample size
scale
secondary
service
Standard
standard care
status
Study protocol
survivor
Survivors
Template
tested
Trial
trial protocol
United Kingdom
university
usual care
Version
website
[DOI] 10.1186/s13063-020-04805-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04805-1 PMC 바로가기 [Article Type] Letter
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study
Research article
[키워드] acute respiratory distress syndrome
acute respiratory illness
approach
arterial oxygen tension
Bacteremia
benefit
Biomarker
Biomarkers
Blood urea nitrogen
C5 inhibitor
caused
changes in
clinical laboratory
complement
Complement pathway
conjugated bilirubin
coronavirus
COVID-19
Cytokines
decrease
eculizumab
Efficacy and safety
finding
fraction
funding
Hemolysis
hemorrhage
hypoxia
IMPROVE
Inflammation
inhibitor
intensive care
Laboratory
Lactate
log-rank test
nonrandomized
oxygen
pathway
Patient
patients treated
Platelet
Pneumonia
Primary outcome
Prothrombin time
rapid increase
reduce
reduced
SARS-COV-2 infection
Sepsis
Serious Adverse Event
severe COVID-19
significantly more
standard care
survival
treated
Treatment
Ventilator-associated pneumonia
viral infection
[DOI] 10.1016/j.eclinm.2020.100590 [Article Type] Research article
[DOI] 10.1016/j.eclinm.2020.100590 [Article Type] Research article
Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 28-day mortality
accompany
acute lung injury
adverse event
airway
All participant
allergic
anti-COVID19 IVIG
Anti-viral
Antibiotics
assigned
assisted ventilation
autoimmune disorder
blinded
Blood oxygen saturation
blood pressure
C-IVIG
Care
Clinical efficacy
Comparator group
convalescent plasma
COVID-19
COVID19
criteria
Critically ill
Critically ill patient
CRP
current
disorder
dosage
Dyspnea
excluded
Follow-up
four group
group
hemodynamic
hemolytic anemia
hospital
hospital discharge
Hospital stay
hypersensitivity
ICU
IgA deficiency
Ill
immunization
Immunoglobulin
include
infected individual
Inflammation
information
inotropic agent
Intervention
intervention arm
Isolation
Karachi
kidney
Kidney failure
lung infiltrate
maintain
Manifestations
medication
Meningitis
MONITOR
multiple organ dysfunction
nasopharyngeal
neutrophil lymphocyte ratio
number
objective
observé
oropharyngeal swabs
outcome
PaO
parallel-group
participant
Passive
passive immunization
Patient
patients
positive SARS-CoV-2 PCR
pregnant females
Primary outcome
protocol
randomised
randomised controlled
randomised controlled trial
randomization
receive
recruited
Registered
reported
Respiratory failure
respiratory rate
Sample size
sealed
Septic shock
shifting
single dose
standard care
status
Steroids
Study protocol
Support
symptoms of COVID-19
therapy
thromboembolic
Total
Treatment
Trial
university
website
were excluded
with COVID-19
[DOI] 10.1186/s13063-020-04839-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04839-5 PMC 바로가기 [Article Type] Letter
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
Letter
[키워드] 1:1
accompany
Admission
age
alcohol
allocation concealment
ALT/AST
Arm
assigned
Beta
block-randomization
Blood
body temperature
Care
clinical
Clinical improvement
clinical trial
comparator
Confirmed
control group
COVID
COVID-19
COVID-2019
CT scan
death
discharge
disease
dissemination
drug
duration of hospitalization
Effect
Effectiveness
element
eligibility criteria
exclusion criteria
fatigue
group
headache
Health
High dose
High-dose
hospital
hospital discharge
Hospitalization
improvement
incidence
include
Infection
information
Interaction
interferon beta
Interferon beta-1a
Interferon-β 1a
intervention group
Intubated
Invasive mechanical ventilation
investigator
Kaletra
Laboratory results
lactating women
Last
less
limit
Loghman Hakim Hospital
Lopinavir/ritonavir
low dose
low-dose
masking
mechanical ventilation
Medical Sciences
moderate
Mortality
nasal
Non-invasive
number
objective
open label
Open-label
outcome
oxygen saturation
oxygen support
package
parallel group
participant
Patient
pregnant
Primary outcome
primary outcome measure
professional
protocol
R software
Radiation
randomised
randomization
randomization sequence
Randomized
Randomized controlled trial
Randomly
receive
Recigen
recruitment
refusal
regimen
Registered
Research
respiratory rate
Ritonavir
RT-PCR
RT-PCR test
Sample size
SARS-CoV-2
sealed
secondary
secondary outcome
seven-category ordinal scale
severe disease
Shortness of breath
single center
standard care
status
Study protocol
Symptom
the patient
therapeutic
time
treated
treatment groups
Trial
two groups
university
version 3.6.1
website
World Health Organization
[DOI] 10.1186/s13063-020-04812-2 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04812-2 PMC 바로가기 [Article Type] Letter
Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial
중증 COVID-19 환자의 회복기 혈장 수혈 요법- 안전성, 효능 및 용량 반응 연구: 2상 무작위 대조 시험 연구 프로토콜의 구조화된 요약
Letter
[키워드] (neutrophil
24 hour
24 hours
allergic
allergic reaction
Antibody titre
Arm
ARMS
automated
blinded
Blinding
body temperature
BSMMU
Care
checked
Clinical improvement
collaboration
collected
comparator
computer
Controlled
Controlled trial
convalescent plasma
COVID-19
creatinine
criteria
CRP
CT scan
deaths
defined
diastolic
discharge
dissemination
Donor
donors
dose
dose response
effective
effective dose
Efficacy
Efficacy and safety
element
ELISA
end point
enrolled
Evidence
evidence of
excluded
expected
FiO2
generate
Health Organization
hospital
Hospital stay
ICU
identify
in-hospital mortality
inclusion criteria
initial
intervention arms
Laboratory
laboratory parameter
Laboratory parameters
Laboratory tests
lactating women
lung
lymphocyte
multi-arm
multicentre
neutralizing antibody
neutrophil
normality
number
objective
open
outcome
Oxford
oxygen
oxygen saturations
PaO2
paO2/fiO2
participant
Participants
Patient
PCR assay
performed
plasma
Plasma transfusion
positive
pregnant
Primary outcome
proportion
protocol
random number table
randomised
Randomized controlled trial
RCT
receive
recorded
recording
recruit
recruited
recruitment
reduction in
required
respiratory
respiratory distress
respiratory rate
respiratory symptoms
room air
RT-PCR
RT-PCR assay
Sample size
sample size calculation
SARS-CoV-2
secondary outcome
serum creatinine
Serum ferritin
Seven
Severe case
severe cases
severe COVID-19
severe COVID-19 patient
severe COVID-19 patients
Severe patient
severe patients
Severe respiratory distress
Sex
SGOT
SGPT
SpO2
sputum
standard care
status
Study protocol
Support
systolic
the patient
therapy
These data
titre
transfusion
Treatment
Trial
university
University of Oxford
ventilator
website
World Health Organization
X-ray
[DOI] 10.1186/s13063-020-04734-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04734-z PMC 바로가기 [Article Type] Letter
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics
실용적인 무작위 통제 시험에서 코로나바이러스 질병 2019 바이러스 동력학에 대한 하이드록시클로로퀸의 효능 부족 보고
Article
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
addition
Admission
age
Antiviral effect
antiviral effects
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
dose
drug
Efficacy
eligible
FIVE
greater
Human
Hydroxychloroquine
hydroxychloroquine therapy
Identifier
infected with SARS-CoV-2
lack
moderately severe COVID-19
Older
Oropharyngeal
patients hospitalized
positive patient
Pragmatic
Randomized
Randomized controlled trial
Randomized controlled trials
respiratory
SARS-CoV-2
SARS-CoV-2 oropharyngeal viral load
Seven
significantly
standard care
study inclusion
Therapeutics
therapy
Treatment
treatment of COVID-19
use of hydroxychloroquine
Viral
viral infection
viral kinetics
Viral load
[DOI] 10.1038/s41467-020-19056-6 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41467-020-19056-6 PMC 바로가기 [Article Type] Article